vorinostat has been researched along with Diarrhea in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 9.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 5.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| " One week later, daily vorinostat dosing was begun and continued until toxicity or disease progression occurred." | 2.75 | Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. ( Belani, CP; Beumer, JH; Egorin, MJ; Harvey, RD; Holleran, J; Ivy, SP; Kummar, S; Lin, Y; LoRusso, P; Ramalingam, SS; Sarantopoulos, J; Shibata, S; Yerk, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hofmeister, CC | 1 |
| Williams, N | 1 |
| Geyer, S | 1 |
| Hade, EM | 1 |
| Bowers, MA | 1 |
| Earl, CT | 1 |
| Vaughn, J | 1 |
| Bingman, A | 1 |
| Humphries, K | 1 |
| Lozanski, G | 1 |
| Baiocchi, RA | 1 |
| Jaglowski, SM | 1 |
| Blum, K | 1 |
| Porcu, P | 1 |
| Flynn, J | 1 |
| Penza, S | 1 |
| Benson, DM | 1 |
| Andritsos, LA | 1 |
| Devine, SM | 1 |
| Ramalingam, SS | 1 |
| Kummar, S | 1 |
| Sarantopoulos, J | 1 |
| Shibata, S | 1 |
| LoRusso, P | 1 |
| Yerk, M | 1 |
| Holleran, J | 1 |
| Lin, Y | 1 |
| Beumer, JH | 1 |
| Harvey, RD | 1 |
| Ivy, SP | 1 |
| Belani, CP | 1 |
| Egorin, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma[NCT00561418] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median follow up of living patients (NCT00561418)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Vorinostat (SAHA) | 23.2 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease(SD) | Not evaluable | |
| Vorinostat (SAHA) | 13 | 3 | 2 | 5 |
NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | ||||
|---|---|---|---|---|---|
| Fatigue (Grade 1, 2) | Lymphopenia (Grade 1-4) | Thrombocytopenia (Grade 1-3) | Leukopenia (Grade 1-3) | Anemia (Grade 1-3) | |
| Vorinostat (SAHA) | 12 | 11 | 11 | 10 | 10 |
2 trials available for vorinostat and Diarrhea
| Article | Year |
|---|---|
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
Topics: Administration, Oral; Adult; Aged; Child; Combined Modality Therapy; Diarrhea; Disease-Free Survival | 2015 |
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Topics: Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Fatig | 2010 |